Randomized, Open-label Phase II Trial to Assess the Safety and Immunogenicity of MVA-BN Smallpox Vaccine When Increasing the Number of Injections Compared to the Standard Regimen in Immunocompromised Subjects With HIV Infection
Phase of Trial: Phase II
Latest Information Update: 24 Jul 2017
Price : $35 *
At a glance
- Drugs Smallpox vaccine (Primary)
- Indications Smallpox
- Focus Adverse reactions
- Sponsors Bavarian Nordic
- 31 Aug 2018 Biomarkers information updated
- 20 Jul 2017 Status changed from active, no longer recruiting to completed.
- 26 Apr 2016 Status changed from recruiting to active, no longer recruiting.